ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

Fisher To Direct Wilmot CC

October 5, 2001

Data collection Completed In NCI Study of BRACA1

August 16, 1996

In Brief: CCIRC Recommends Central Oncology Group For Phasing Out; Rogers Backs Pay Raise

March 5, 1976

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

Studies On Diet Add To Information On Fiber, Fat, Meat

April 5, 1991

Ellen Stoval Calls For More Funding for All Cancer Research

June 6, 1997